Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
UPPTHERA currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This active matter is concentrated under 1 distinct examiner and 1 distinct art unit, indicating a focused prosecution footprint. The alignment of the count of pending actions with the count of examiners suggests that the current portfolio strategy is tied to a specific technological niche or a patent family.
The busiest examiner for the portfolio is BAUER, NICOLA MARIA, who is responsible for 1 busiest examiner pending office action. Because this figure matches the total volume of pending office actions for the company, this specific examiner holds the responsibility for the portfolio's active prosecution. Practitioners should focus their preparation on the specific preferences and historical trends of this individual to resolve the outstanding matter.
With the distinct art unit involved, the prosecution environment is narrow. The alignment of the distinct examiner with the total volume of pending office actions means that the outcome of this interaction will define the immediate prosecution success for UPPTHERA in the Biotechnology & Pharmaceuticals sector. This concentration allows for a targeted response strategy rather than a broad approach, as the practitioner accounts for the standards of the technical group.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BAUER, NICOLA MARIA | 1 | 58.3% | +50.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17914545 | PYRAZOLO QUINAZOLINE DERIVATIVE COMPOUNDS INDUCING SELECTIVE DEGRADATION OF PLK1 | BAUER, NICOLA MARIA | 15d |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17914545 | PYRAZOLO QUINAZOLINE DERIVATIVE COMPOUNDS INDUCING SELECTIVE DEGRADATION OF PLK1 | BAUER, NICOLA MARIA | 1621 | §103 | Final Rejection | 15d | Pending | Sep 26, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial